Claritev Corporation CTEV
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -55.49%
- 1 year
- -59.09%
5D -7.64 (-27.57%)
- Market cap
- 324.93M
- Revenue (ttm)
- 935.54M
- Profit margin
- -70.91%
- EPS (ttm)
- -16.41
- Shares out
- 16.47M
- YTD return
- -55.49%
- 1-year return
- -59.09%
- 50-day average
- 56.07
- Volume
- 271.03K
- Avg volume
- 207.43K
- Open
- 22.78
- Previous close
- 22.30
- Day's range
- 19.02 – 22.62
- 52-week range
- 11.50 – 55.50
- Beta
- 0.58
- Price target
- 70.50 (+270.5%)
Key statistics
- 200-day average
- 30.44
- Enterprise value
- 5.61B
- Price / sales
- 1.05
- Revenue growth
- 3.50%
- Free cash flow
- 200.30M
- Total cash
- 56.39M
- Total debt
- 4.66B
- Return on equity
- -235.47%
- Short % of float
- 8.20%
Fundamental scorecard
5 of 25 checks passed on CTEV’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 6, 2025 | Jun 1, 2025 | — | 0.32 | +3.01 | +111.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2025 | Piper Sandler | main | Overweight | Overweight |
| May 29, 2025 | Piper Sandler | up | Neutral | Overweight |
| Mar 10, 2025 | Piper Sandler | main | Neutral | Neutral |
| Jan 10, 2025 | Citigroup | main | Neutral | Neutral |
About Claritev Corporation
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- claritev.com
News
Saudi Arabia's Wealth Fund Has 80% of Its U.S. Stock Portfolio in SpaceX
Claritev (NYSE:CTEV) Major Shareholder Acquires $1,221,000.00 in Stock
Claritev (NYSE:CTEV) vs. OneMedNet (NASDAQ:ONMD) Head-To-Head Analysis
Claritev Corporation (CTEV) Q3 2026 Earnings Call Transcript
What Claritev (CTEV) Said on Its Q3 Earnings Call
Claritev Q3 2026 Earnings Call Transcript
Claritev Corporation (CTEV) Reports Q3 Loss, Tops Revenue Estimates Claritev Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.038B-$1.043B vs $1.014B Est
Claritev Q3 EPS $(3.64) Beats $(3.81) Estimate, Sales $268.311M Beat $256.129M Estimate
Claritev Corporation Reports Third Quarter 2026 Results
Your note
Sign in to keep a note on CTEV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLARKE RICHARD A | Director | Stock Award(Grant) | Apr 29, 2025 | 15,357 |
| COLALUCA ANTHONY JR | Director | Stock Award(Grant) | Apr 29, 2025 | 20,857 |
| DALTON TRAVIS | Chief Executive Officer | Purchase | Aug 10, 2025 | 0 |
| GARIS DOUGLAS MICHAEL | Chief Financial Officer | Purchase | May 18, 2025 | 143,861 |
| HARRIS C. MARTIN M.D. | Director | Stock Award(Grant) | Apr 29, 2025 | 15,305 |
| HOGGE JEROME | Chief Operating Officer | Purchase | Aug 6, 2025 | 90,023 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| H&F Corporate Investors VIII, Ltd. | 32.70% | 5,387,858 | 321.57M | Jun 29, 2025 |
| Ares Management LLC | 11.31% | 1,863,105 | 111.20M | Jun 29, 2025 |
| Public Investment Fund | 7.78% | 1,281,250 | 76.47M | Jun 29, 2025 |
| CPV Partners, LLC | 3.01% | 495,258 | 29.56M | Jun 29, 2025 |
| Vanguard Group Inc | 2.90% | 477,937 | 28.53M | Jun 29, 2025 |
| Blackrock Inc. | 2.83% | 466,716 | 27.86M | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.82% | 299,782 | 17.89M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.00% | 164,335 | 9.81M | Jun 29, 2025 |
| Invesco Exch-Trd Fd. TRT II-Invesco Dorsey Wright SmallCap Momentum ET | 1.00% | 164,961 | 9.85M | Jun 29, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.59% | 97,397 | 5.81M | Jun 29, 2025 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.47% | 77,138 | 4.60M | Jun 29, 2025 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.36% | 60,046 | 3.58M | Jun 29, 2025 |
